Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
08 nov. 2022 16h01 HE
|
Coherus BioSciences, Inc.
– UDENYCA® net sales of $45.4 million in the third quarter 2022 –– CIMERLI™ launched in the United States on October 3rd –– Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and...
[Latest] Global Microbial Fermentation Technology Market Size/Share Worth USD 52.12 Billion by 2030 at a 7.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
07 nov. 2022 07h30 HE
|
Custom Market Insights
Sandy, Utah, USA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Microbial Fermentation Technology Market Size, Trends, and Insights By Product...
Global Biosimilars Market Size to reach USD 56.40 Billion by 2030 | CAGR 22.80 %; Spherical Insights & Consulting
01 nov. 2022 06h00 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Global Biosimilars Market Size was valued at USD 17.6 Billion in 2021, the market is projected to grow USD 56.40 Billion in 2030, at a...
The Global Biosimilars Market to Register Growth at a Massive CAGR of 21.54% During the Forecast Period (2022–2027) | DelveInsight
20 oct. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The Global Biosimilars Market to Register Growth at a Massive CAGR of 21.54% During the Forecast Period (2022–2027) | DelveInsight The biosimilars...
Global Biosimilars Market to Hit Sales of $68.95 Billion by 2028 | Biocon, Sanofi, and Ely Lilly and Company Hold Over 90% of Insulin Biosimilars Market
03 août 2022 10h58 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- According to a study by SkyQuest Technology, biosimilars market generated $12.24 billion in global sales in 2020. This is an 85% increase from the...
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
07 juil. 2022 08h35 HE
|
Alvotech
AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies Eylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10...
Short-Acting Insulin Market is projected to reach USD 10.28 Billion by 2030, growing at a CAGR of 2%: Straits Research
06 juil. 2022 12h50 HE
|
Straits Research
New York, United States, July 06, 2022 (GLOBE NEWSWIRE) -- The market for short-acting insulin is highly consolidated, with Sanofi, Novo Nordisk, and Eli Lilly serving as the three most important...
Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and Iceland
22 juin 2022 18h56 HE
|
Alvotech
After the largest debut by an Icelandic company on a U.S. stock exchange, Alvotech is set to list its shares under the ticker symbol “ALVO” on the Nasdaq First North Growth Market in Iceland...
Viðauki við Skráningarskjal
22 juin 2022 18h25 HE
|
Alvotech
Í tengslum við birtingu á formi 20-F hjá bandaríska verðbréfaeftirlitinu (SEC) þá hefur Alvotech birt viðauka dagsettan 22. júní 2022 við skráningarskjal félagsins dagsett 21. júní 2022. Við birtingu...
Supplement to the Company Description
22 juin 2022 18h25 HE
|
Alvotech
In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC), Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June...